Anticorps Monoclonal anti-NeutraKine® BMP-7
NeutraKine® BMP-7 Monoclonal Antibody for FC (Intra), Neutralization, ELISA
Hôte / Isotype
Mouse / IgG1
Réactivité testée
Humain, souris
Applications
Neutralization, FC (Intra), ELISA
Conjugaison
Non conjugué
CloneNo.
3E9G7
N° de cat : 69011-1-Ig
Synonymes
Galerie de données de validation
Neutralization |
Informations sur le produit
69011-1-Ig cible NeutraKine® BMP-7 dans les applications de Neutralization, FC (Intra), ELISA et montre une réactivité avec des échantillons Humain, souris
Réactivité | Humain, souris |
Hôte / Isotype | Mouse / IgG1 |
Clonalité | Monoclonal |
Type | Anticorps |
Immunogène | human Humankine BMP-7 protein HZ-1229 |
Nom complet | bone morphogenetic protein 7 |
Symbole du gène | BMP7 |
Identification du gène (NCBI) | 655 |
Conjugaison | Non conjugué |
Forme | Lyophilized Powder |
Méthode de purification | Purification par protéine G |
Tampon de stockage | PBS stérile. |
Endotoxin | <0.1 EU/μg |
Reconstitution | This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use. |
Stability and Storage | Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products. |
Informations générales
The bone morphogenetic proteins (BMPs) are a family of secreted signaling molecules that can induce ectopic bone growth. Many BMPs are part of the transforming growth factor-beta (TGFB) superfamily. BMPs were originally identified by an ability of demineralized bone extract to induce endochondral osteogenesis in vivo in an extraskeletal site.
BMP7, also known as osteogenic protein-1 or OP-1, plays a key role in the transformation of mesenchymal cells into bone and cartilage. BMP7 may be involved in bone homeostasis (PMID: 15621726). It is expressed in the brain, kidneys and bladder. BMP7 is also present in cancers, including breast, prostate, and colon cancers, in which it is implicated in regulating cancer cell proliferation (PMID: 16419056, PMID: 15531927). Overexpression of BMP7 mRNA in colorectal cancer patients was significantly associated with poor prognosis and low overall survival (PMID: 18259822). Recent studies suggest that high-expression level of BMP7 serves as a biomarker for poor prognosis for HCC (PMID: 23179403).
This antibody can be used to neutralize the bioactivity of BMP-7.